圓祥生技logo
Contact LinkedIn
English
01.jpg 01-1.jpg
circle01.png circle02.png circle03.png
有效性
c01-1.svg c01-2.svg
可靠
c02-1.svg c02-1-1.svg c02-2.png
創新
c03-1.svg c03-1-1.svg c03-2.svg
bg01.svg bg02.svg
通過以機制為基礎的藥物設計<br>專注於疾病特異性靶點
通過以機制為基礎的藥物設計<br>專注於疾病特異性靶點

通過以機制為基礎的藥物設計
專注於疾病特異性靶點

Mechanism-based drug design targeting tumor-associated antigens
提供安全、有效<br>和具有成本效益的藥物
提供安全、有效<br>和具有成本效益的藥物

提供安全、有效
和具有成本效益的藥物

Delivery safe, efficacious
and affordable medicines

AP Biosciences Milestone

2024

Successfully raised 22 million in funding for B round
Series D round of $38 Million was closed AP402 was approved by TGA and HREC to initiate its first-in-human Phase 1/2 trial in Australia

2023

Patient enrollment started for the Phase I trial of AP505/B1962 at Shanghai Pulmonary Hospital

Listed on the Emerging Stock Market Initiation of patient enrollment for Phase III trial of IBI302 for nAMD, originated by AP Bio and licensed to Innovent Patient enrollment started for the Phase I trial of AP505/B1962 which was licensed to Tasly Pharmaceutical Group for China right APBio listed on TPEx Emerging Stock Board (6945.TW) Enrollment of the first patient for Phase I trial of AP203

2022

Successfully secured 25 million in funding for the C round
Series C round of $25 Million was closed

2020

Successfully raised 22 million in funding for B round
Series B round of $22 Million was closed successfully

2019

AP505/B1962 was licensed out to Tasly Biopharmaceutical for development, production, and marketing rights in China, Hong Kong and Macao
AP505/B1962 was licensed out to Tasly Biopharmaceutical for development, production, and marketing rights in China, Hong Kong and Macao

Stock Symbol

6945.TW

stock01.png
Governance
Learn More
stock02.png
Investor Information
Learn More
stock03.png
Financial
Learn More

News

Learn More

05.22 2025

[BioWorld] AP402 Clinical Trial Featured by Global News Outlet BioWorld

Exclusive interview with Dr. Jeng Her, CEO of AP Biosciences. AP402, targeting HER2-resistant tumors, is currently undergoing Phase I/II clinical trials in Australia.

04.30 2025

[Media Feature] AP402 Clinical Trial Featured by U.S. Patient Platform WhatNext

AP402, was recently featured in WhatNext, a trusted U.S.-based platform focused on cancer patient education and clinical trial awareness

04.29 2025

AP Biosciences Presents AP402 Preclinical Data at AACR

AP Biosciences Presents Preclinical Data on p95HER/CD137 T-Cell Engager at American Association of Cancer Research Annual Meeting

04.22 2025

FPD in Phase 1/2 Clinical Trials of AP402 for HER2+ Cancer Patients

AP Biosciences Doses First Patient in Phase 1/2 Clinical Trials of AP402 for HER2+ Cancer Patients

04.22 2025

AP Biosciences to Present New Preclinical Data at 2025 AACR Annual Meeting

Present new preclinical data for AP402, at the 2025 AACR Annual Meeting
↑
關閉

建議您使用以下瀏覽器觀看本網站，
以獲得最佳瀏覽效果。

要下載瀏覽器，請直接點擊以下: